Search alternatives:
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a step » _ step (Expand Search)
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a step » _ step (Expand Search)
-
17941
-
17942
Stress responses after knockdown of octopamine receptor OAMB and serotonin receptor 5-HT<sub>1A</sub> in IPCs.
Published 2014“…In an earlier study it was shown that 5-HT<sub>1A</sub> knockdown decreased starvation resistance <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0099732#pone.0099732-Luo1" target="_blank">[22]</a>. …”
-
17943
-
17944
Illustration of controller breakdown of the scheme in Fig 2 when inflows to <i>A</i> exceed the outflows from <i>A</i>.
Published 2024“…Panel b: <i>E</i> as a function of time for the same <i>k</i><sub>1</sub> steps as in panel a. …”
-
17945
-
17946
Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus
Published 2012“…<div><p>Cleft Lip and Palate Transmembrane Protein 1-Like (CLPTM1L), resides in a region of chromosome 5 for which copy number gain has been found to be the most frequent genetic event in the early stages of non-small cell lung cancer (NSCLC). …”
-
17947
Table 1_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.xlsx
Published 2025“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
-
17948
Table 1_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.xlsx
Published 2025“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”
-
17949
-
17950
-
17951
-
17952
Image_1_Exosomal miR-2276-5p in Plasma Is a Potential Diagnostic and Prognostic Biomarker in Glioma.TIF
Published 2021“…</p>Results<p>The exosomal miR-2276-5p in glioma patients had a significantly decreased expression, compared with non-glioma patients (p < 0.01). …”
-
17953
-
17954
datasheet1_Krupple-Like Factor 5 is a Potential Therapeutic Target and Prognostic Marker in Epithelial Ovarian Cancer.pdf
Published 2020“…Identifying novel molecular therapeutic targets is highly needed in the management of EOC. Krupple-like factor 5 (KLF5), a zinc-finger transcriptional factor, is highly expressed in a variety of cancer types. …”
-
17955
-
17956
-
17957
Table_1_Exosomal miR-2276-5p in Plasma Is a Potential Diagnostic and Prognostic Biomarker in Glioma.doc
Published 2021“…</p>Results<p>The exosomal miR-2276-5p in glioma patients had a significantly decreased expression, compared with non-glioma patients (p < 0.01). …”
-
17958
Image 5_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).tif
Published 2025“…R-bibliometrix, VOSviewer, and CiteSpace were employed to conduct quantitative analysis and visualize research trends and factors influencing QOL. Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”
-
17959
-
17960